Journal of Yeungnam Medical Science

영남대 의대 학술지 편집위원회 (Yeungnam University College of Medicine, Yeungnam University Institute Medical Science)
권호 표지
DOI QR코드

DOI QR Code

Long-term management of Graves disease: a narrative review

  • Hyo-Jeong Kim (Division of Endocrinology and Metabolism, Department of Internal Medicine, Nowon Eulji University Hospital, Eulji University School of Medicine)
  • 투고 : 2022.06.12
  • 심사 : 2022.08.10
  • 발행 : 2023.01.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Graves disease (GD) is the most common cause of hyperthyroidism, accounting for more than 90% of cases in Korea. Patients with GD are treated with any of the following: antithyroid drugs (ATDs), radioactive iodine (RAI) therapy, or thyroidectomy. Most patients begin treatment with ATDs, and clinical guidelines suggest that the appropriate treatment period is 12 to 18 months. While RAI treatment and surgery manage thyrotoxicosis by destroying or removing thyroid tissue, ATDs control thyrotoxicosis by inhibiting thyroid hormone synthesis and preserving the thyroid gland. Although ATDs efficiently control thyrotoxicosis symptoms, they do not correct the main etiology of GD; therefore, frequent relapses can follow. Recently, a large amount of data has been collected on long-term ATDs for GD, and low-dose methimazole (MMZ) is expected to be a good option for remission. For the long-term management of recurrent GD, it is important to induce remission by evaluating the patient's drug response, stopping ATDs at an appropriate time, and actively switching to surgery or RAI therapy, if indicated. Continuing drug treatment for an extended time is now encouraged in patients with a high possibility of remission with low-dose MMZ. It is also important to pay attention to the quality of life of the patients. This review aimed to summarize the appropriate treatment methods and timing of treatment transition in patients who relapsed several times while receiving treatment for GD.

키워드

참고문헌

  1. Seo GH, Kim SW, Chung JH. Incidence & prevalence of hyperthyroidism and preference for therapeutic modalities in Korea. J Korean Thyroid Assoc 2013;6:56-63. https://doi.org/10.11106/jkta.2013.6.1.56
  2. Mohlin E, Filipsson Nystrom H, Eliasson M. Long-term prognosis after medical treatment of Graves' disease in a northern Swedish population 2000-2010. Eur J Endocrinol 2014;170:419-27. https://doi.org/10.1530/EJE-13-0811
  3. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 2016;26:1343-421. https://doi.org/10.1089/thy.2016.0229
  4. Kahaly GJ, Bartalena L, Hegedus L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association guideline for the management of Graves' hyperthyroidism. Eur Thyroid J 2018;7:167-86. https://doi.org/10.1159/000490384
  5. Shi H, Sheng R, Hu Y, Liu X, Jiang L, Wang Z, et al. Risk factors for the relapse of Graves' disease treated with antithyroid drugs: a systematic review and meta-analysis. Clin Ther 2020;42:662-75. https://doi.org/10.1016/j.clinthera.2020.01.022
  6. Garcia-Mayor RV, Alvarez-Vazquez P, Fluiters E, Valverde D, Andrade A. Long-term remission following antithyroid drug withdrawal in patients with Graves' hyperthyroidism: parameters with prognostic value. Endocrine 2019;63:316-22. https://doi.org/10.1007/s12020-018-1785-z
  7. Masiello E, Veronesi G, Gallo D, Premoli P, Bianconi E, Rosetti S, et al. Antithyroid drug treatment for Graves' disease: baseline predictive models of relapse after treatment for a patient-tailored management. J Endocrinol Invest 2018;41:1425-32. https://doi.org/10.1007/s40618-018-0918-9
  8. Vos XG, Endert E, Zwinderman AH, Tijssen JG, Wiersinga WM. Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves' hyperthyroidism. J Clin Endocrinol Metab 2016;101:1381-9. https://doi.org/10.1210/jc.2015-3644
  9. Smith TJ, Hegedus L. Graves' disease. N Engl J Med 2016;375:1552-65. https://doi.org/10.1056/NEJMra1510030
  10. Morshed SA, Latif R, Davies TF. Delineating the autoimmune mechanisms in Graves' disease. Immunol Res 2012;54:191-203. https://doi.org/10.1007/s12026-012-8312-8
  11. Davies TF, Andersen S, Latif R, Nagayama Y, Barbesino G, Brito M, et al. Graves' disease. Nat Rev Dis Primers 2020;6:52.
  12. Antonelli A, Ferrari SM, Ragusa F, Elia G, Paparo SR, Ruffilli I, et al. Graves' disease: epidemiology, genetic and environmental risk factors and viruses. Best Pract Res Clin Endocrinol Metab 2020;34:101387.
  13. Kahaly GJ, Olivo PD. Graves' disease. N Engl J Med 2017;376:184.
  14. Brito JP, Castaneda-Guarderas A, Gionfriddo MR, Ospina NS, Maraka S, Dean DS, et al. Development and pilot testing of an encounter tool for shared decision making about the treatment of Graves' disease. Thyroid 2015;25:1191-8. https://doi.org/10.1089/thy.2015.0277
  15. Azizi F, Malboosbaf R. Long-term antithyroid drug treatment: a systematic review and meta-analysis. Thyroid 2017;27:1223-31. https://doi.org/10.1089/thy.2016.0652
  16. Azizi F, Amouzegar A, Tohidi M, Hedayati M, Khalili D, Cheraghi L, et al. Increased remission rates after long-term methimazole therapy in patients with Graves' disease: results of a randomized clinical trial. Thyroid 2019;29:1192-200. https://doi.org/10.1089/thy.2019.0180
  17. Azizi F. Long-term treatment of hyperthyroidism with antithyroid drugs: 35 years of personal clinical experience. Thyroid 2020;30:1451-7. https://doi.org/10.1089/thy.2019.0814
  18. Mooij CF, Cheetham TD, Verburg FA, Eckstein A, Pearce SH, Leger J, et al. 2022 European Thyroid Association guideline for the management of pediatric Graves' disease. Eur Thyroid J 2022;11:e210073.
  19. Bandai S, Okamura K, Fujikawa M, Sato K, Ikenoue H, Kitazono T. The long-term follow-up of patients with thionamidetreated Graves' hyperthyroidism. Endocr J 2019;66:535-45. https://doi.org/10.1507/endocrj.EJ18-0418
  20. Walter MA, Briel M, Christ-Crain M, Bonnema SJ, Connell J, Cooper DS, et al. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ 2007;334:514.
  21. Walter MA, Christ-Crain M, Schindler C, Muller-Brand J, Muller B. Outcome of radioiodine therapy without, on or 3 days off carbimazole: a prospective interventional three-group comparison. Eur J Nucl Med Mol Imaging 2006;33:730-7. https://doi.org/10.1007/s00259-006-0092-8
  22. Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, et al. The 2021 European Group on Graves' Orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. Eur J Endocrinol 2021;185:G43-67. https://doi.org/10.1530/EJE-21-0479
  23. Guo Z, Yu P, Liu Z, Si Y, Jin M. Total thyroidectomy vs bilateral subtotal thyroidectomy in patients with Graves' diseases: a meta-analysis of randomized clinical trials. Clin Endocrinol (Oxf) 2013;79:739-46. https://doi.org/10.1111/cen.12209
  24. Langley RW, Burch HB. Perioperative management of the thyrotoxic patient. Endocrinol Metab Clin North Am 2003;32:519-34. https://doi.org/10.1016/S0889-8529(03)00010-0
  25. Abraham P, Avenell A, Park CM, Watson WA, Bevan JS. A systematic review of drug therapy for Graves' hyperthyroidism. Eur J Endocrinol 2005;153:489-98. https://doi.org/10.1530/eje.1.01993
  26. Abraham P, Avenell A, McGeoch SC, Clark LF, Bevan JS. Antithyroid drug regimen for treating Graves' hyperthyroidism. Cochrane Database Syst Rev 2010;2010:CD003420.
  27. Mazza E, Carlini M, Flecchia D, Blatto A, Zuccarini O, Gamba S, et al. Long-term follow-up of patients with hyperthyroidism due to Graves' disease treated with methimazole: comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study. J Endocrinol Invest 2008;31:866-72. https://doi.org/10.1007/BF03346433
  28. Park SY, Kim BH, Kim M, Hong AR, Park J, Park H, et al. The longer the antithyroid drug is used, the lower the relapse rate in Graves' disease: a retrospective multicenter cohort study in Korea. Endocrine 2021;74:120-7. https://doi.org/10.1007/s12020-021-02725-x
  29. Staniforth JU, Erdirimanne S, Eslick GD. Thyroid carcinoma in Graves' disease: a meta-analysis. Int J Surg 2016;27:118-25. https://doi.org/10.1016/j.ijsu.2015.11.027
  30. Papanastasiou A, Sapalidis K, Goulis DG, Michalopoulos N, Mareti E, Mantalovas S, et al. Thyroid nodules as a risk factor for thyroid cancer in patients with Graves' disease: a systematic review and meta-analysis of observational studies in surgically treated patients. Clin Endocrinol (Oxf) 2019;91:571-7. https://doi.org/10.1111/cen.14069
  31. Santos RB, Romaldini JH, Ward LS. A randomized controlled trial to evaluate the effectiveness of 2 regimens of fixed iodine (131I) doses for Graves disease treatment. Clin Nucl Med 2012;37:241-4. https://doi.org/10.1097/RLU.0b013e31823ea6e0
  32. Park H, Kim HI, Park J, Park SY, Kim TH, Chung JH, et al. The success rate of radioactive iodine therapy for Graves' disease in iodine-replete area and affecting factors: a single-center study. Nucl Med Commun 2020;41:212-8. https://doi.org/10.1097/MNM.0000000000001138
  33. Abraham-Nordling M, Bystrom K, Torring O, Lantz M, Berg G, Calissendorff J, et al. Incidence of hyperthyroidism in Sweden. Eur J Endocrinol 2011;165:899-905. https://doi.org/10.1530/EJE-11-0548
  34. Simon M, Rigou A, Le Moal J, Zeghnoun A, Le Tertre A, De Crouy-Chanel P, et al. Epidemiology of childhood hyperthyroidism in france: a nationwide population-based study. J Clin Endocrinol Metab 2018;103:2980-7. https://doi.org/10.1210/jc.2018-00273
  35. Leger J, Gelwane G, Kaguelidou F, Benmerad M, Alberti C; French Childhood Graves' Disease Study Group. Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves' disease: national long-term cohort study. J Clin Endocrinol Metab 2012;97:110-9. https://doi.org/10.1210/jc.2011-1944
  36. Leger J, Carel JC. Management of endocrine disease: arguments for the prolonged use of antithyroid drugs in children with Graves' disease. Eur J Endocrinol 2017;177:R59-67. https://doi.org/10.1530/EJE-16-0938
  37. Azizi F, Takyar M, Madreseh E, Amouzegar A. Long-term methimazole therapy in juvenile Graves' disease: a randomized trial. Pediatrics 2019;143:e20183034.
  38. Wood CL, Cole M, Donaldson M, Dunger DB, Wood R, Morrison N, et al. Randomised trial of block and replace vs dose titration thionamide in young people with thyrotoxicosis. Eur J Endocrinol 2020;183:637-45. https://doi.org/10.1530/EJE-20-0617
  39. van Lieshout JM, Mooij CF, van Trotsenburg AS, Zwaveling-Soonawala N. Methimazole-induced remission rates in pediatric Graves' disease: a systematic review. Eur J Endocrinol 2021;185:219-29. https://doi.org/10.1530/EJE-21-0077
  40. Lane LC, Rankin J, Cheetham T. A survey of the young person's experience of Graves' disease and its management. Clin Endocrinol (Oxf) 2021;94:330-40. https://doi.org/10.1111/cen.14359
  41. Azizi F, Abdi H, Amouzegar A. Control of Graves' hyperthyroidism with very long-term methimazole treatment: a clinical trial. BMC Endocr Disord 2021;21:16.
  42. El Kawkgi OM, Ross DS, Stan MN. Comparison of long-term antithyroid drugs versus radioactive iodine or surgery for Graves' disease: a review of the literature. Clin Endocrinol (Oxf) 2021;95:3-12. https://doi.org/10.1111/cen.14374
  43. Alexander EK, Larsen PR. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 2002;87:1073-7.
  44. Sundaresh V, Brito JP, Thapa P, Bahn RS, Stan MN. Comparative effectiveness of treatment choices for Graves' hyperthyroidism: a historical cohort study. Thyroid 2017;27:497-505. https://doi.org/10.1089/thy.2016.0343
  45. Azizi F, Ataie L, Hedayati M, Mehrabi Y, Sheikholeslami F. Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine. Eur J Endocrinol 2005;152:695-701. https://doi.org/10.1530/eje.1.01904
  46. Azizi F, Yousefi V, Bahrainian A, Sheikholeslami F, Tohidi M, Mehrabi Y. Long-term continuous methimazole or radioiodine treatment for hyperthyroidism. Arch Iran Med 2012;15:477-84.
  47. Cooper DS, Goldminz D, Levin AA, Ladenson PW, Daniels GH, Molitch ME, et al. Agranulocytosis associated with antithyroid drugs: effects of patient age and drug dose. Ann Intern Med 1983;98:26-9. https://doi.org/10.7326/0003-4819-98-1-26
  48. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998;338:73-8. https://doi.org/10.1056/NEJM199801083380201
  49. Villagelin D, Romaldini JH, Santos RB, Milkos AB, Ward LS. Outcomes in relapsed Graves' disease patients following radioiodine or prolonged low dose of methimazole treatment. Thyroid 2015;25:1282-90. https://doi.org/10.1089/thy.2015.0195
  50. Ma C, Xie J, Wang H, Li J, Chen S. Radioiodine therapy versus antithyroid medications for Graves' disease. Cochrane Database Syst Rev 2016;2:CD010094.
  51. Watt T, Cramon P, Hegedus L, Bjorner JB, Bonnema SJ, Rasmussen AK, et al. The thyroid-related quality of life measure ThyPRO has good responsiveness and ability to detect relevant treatment effects. J Clin Endocrinol Metab 2014;99:3708-17. https://doi.org/10.1210/jc.2014-1322
  52. Torring O, Watt T, Sjolin G, Bystrom K, Abraham-Nordling M, Calissendorff J, et al. Impaired quality of life after radioiodine therapy compared to antithyroid drugs or surgical treatment for Graves' hyperthyroidism: a long-term follow-upwith the Thyroid-Related Patient-Reported Outcome Questionnaire and 36- Item Short Form Health Status Survey. Thyroid 2019;29:322-31. https://doi.org/10.1089/thy.2018.0315
  53. Ljunggren JG, Torring O, Wallin G, Taube A, Tallstedt L, Hamberger B, et al. Quality of life aspects and costs in treatment of Graves' hyperthyroidism with antithyroid drugs, surgery, or radioiodine: results from a prospective, randomized study. Thyroid 1998;8:653-9. https://doi.org/10.1089/thy.1998.8.653
  54. Abraham-Nordling M, Torring O, Hamberger B, Lundell G, Tallstedt L, Calissendorff J, et al. Graves' disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery. Thyroid 2005;15:1279-86. https://doi.org/10.1089/thy.2005.15.1279
  55. Dale J, Daykin J, Holder R, Sheppard MC, Franklyn JA. Weight gain following treatment of hyperthyroidism. Clin Endocrinol (Oxf) 2001;55:233-9. https://doi.org/10.1046/j.1365-2265.2001.01329.x
  56. Lane LC, Cheetham TD, Perros P, Pearce SH. New therapeutic horizons for Graves' hyperthyroidism. Endocr Rev 2020;41:873-84. https://doi.org/10.1210/endrev/bnaa022
  57. Elia G, Fallahi P, Ragusa F, Paparo SR, Mazzi V, Benvenga S, et al. Precision medicine in Graves' disease and ophthalmopathy. Front Pharmacol 2021;12:754386.
  58. Pearce SH, Dayan C, Wraith DC, Barrell K, Olive N, Jansson L, et al. Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves' hyperthyroidism: a phase I study. Thyroid 2019;29:1003-11. https://doi.org/10.1089/thy.2019.0036
  59. Salvi M, Vannucchi G, Curro N, Campi I, Covelli D, Dazzi D, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. J Clin Endocrinol Metab 2015;100:422-31. https://doi.org/10.1210/jc.2014-3014
  60. Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA, Bahn RS. Randomized controlled trial of rituximab in patients with Graves' orbitopathy. J Clin Endocrinol Metab 2015;100:432-41. https://doi.org/10.1210/jc.2014-2572
  61. Paridaens D, van den Bosch WA, van der Loos TL, Krenning EP, van Hagen PM. The effect of etanercept on Graves' ophthalmopathy: a pilot study. Eye (Lond) 2005;19:1286-9. https://doi.org/10.1038/sj.eye.6701768
  62. Furmaniak J, Sanders J, Young S, Kabelis K, Sanders P, Evans M, et al. In vivo effects of a human thyroid-stimulating monoclonal autoantibody (M22) and a human thyroid-blocking autoantibody (K1-70). Auto Immun Highlights 2011;3:19-25. https://doi.org/10.1007/s13317-011-0025-9
  63. Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med 2017;376:1748-61. https://doi.org/10.1056/NEJMoa1614949
  64. Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EH, Perdok R, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med 2020;382:341-52. https://doi.org/10.1056/NEJMoa1910434